Investor Presentation

Wanbury lnfotech Pvt. Ltd. Re!Jd. Office : BSEL Tech Park, B-wing 10 Floor, Sector-30 A, Opp. Vashi Railway Station, Vashi Navi Mumbai 400 703 Maharashtra, INDIA Tel. : +91-22-6794 2222 WAN BURY Fax : +91-22-6794 2111/333 Website : www.wanbury.com July 01, 2026 To To BSE Limited National Stock Exchange of India Ltd, PJ. Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street Bandra (East), Mumbai -400 001. Mumbai-400 051. Script Code: 524212 Script Code: W ANBURY Dear Sir/Madam, Sub.:Disclosure under Regulation 30 of the SEBI LODR, 2015 - Investors Presentation on 04 & Year ended 31.03.2026 As per Regulation 30 of SEBI LODR, 2015, please find attached herewith copy of Investors Presentation on Audited Financial Results (AFR) for the quarter and year ended 31st March, 2026 and is also available on the website of the Company at www.wanbury.com This is for your information and record. Thanking you. Yours faithfully, For Wanbury Limited Jitendra J. Gandhi Company Secretary Encl.: afa. Towards Better Healthcare Earnings Presentation Q4 & FY26 | July 2026 Wanbury Limited NSE: WANBURY | BSE: 524212 Bloomberg: WANB:IN Inside this Presentation Company Profile Business Profile Financial Profile Company Profile Business Profile Financial Profile API Business Formulations Business API Business Formulations Business Executive Summary 04 Key Performance Indicators 31 Corporate Journey 05 Strategically Curated 14 Re-Building Business 22 5Y P&L Snapshot 32 Product Portfolio Successful Business Turnaround 06 Brand Portfolio 23 5Y Balance Sheet Snapshot 33 World-Class Manufacturing 15 Wanbury at a Glance 07 Infrastructure Strategy & Way Forward 24 5Y Cash Flow Snapshot 34 Business Streams 08 Developed Market 15 Q4 Q FY2 46 E a &rnin g Fs YUpd 2at 6e Earnings Update Capital Markets Overview 35 Board of Directors 09 Focused Business Profile Senior Leadership 10 Regulatory Approvals 16 R&D Capabilities 11 Manufacturing Capabilities 17 Environment, Health & Safety 12 Strategy & Way Forward 18 Safety First Culture 19 Performance Highlights 26 Business Verticals Performance 27 P&L Snapshot 28 Management Commentary 29 Investor Presentation | Wanbury Limited Executive Summary 04 Corporate Journey 05 Successful Business Turnaround 06 Wanbury at a Glance 07 Business Streams 08 Company Board of Directors 09 Senior Leadership 10 R&D Capabilities 11 Profile Environment, Health & Safety 12 01/ COMPANY PROFILE Executive Summary Successful Global market Building new De-risked & turnaround to leaderships in growth drivers in robust balance growth momentum key products API business sheet Operational & financial Globally significant Through launch of an Refinanced debt & healthy turnaround over last 3 years, market share in Anaesthetic in Q4FY26, and internal accruals i.e. moderate now transforming into growth Metformin & Sertraline pipeline of 4 molecules leverage ratio of momentum commercialisation each year ~2X Debt/EBITDA beginning current financial year Established Levers for Formulation global regulatory operating leverage growth approvals & margin expansion story Through brownfield expansion, Turnaround, break-even (in operational scale-up, and FY26), to rebuilding & scale- borrowing cost optimisation up (in FY27) Investor Presentation | Wanbury Limited 01/ COMPANY PROFILE Corporate Journey 1990-2000 2000-2010 2010-2023 2024-Onwards 1990-2000 2000-2010 2010-2023 2024-Onwards Foundation Early Strategic Acquisitions CVoernptourraet ein Ctoo nDseovliedlaotpioedn Markets Challenges Business Turnaround Transformation Growth Foundation & Early Strategic Corporate Consolidation & Challenges & Transformation & Acquisitions Venture into Developed Markets Business Turnaround Growth 1990 2002 Underwent Corporate Debt 2024 Incorporated as Pearl Organics USFDA approval received for Restructuring with Banks Scale up EBITDA to ₹73 crore Pvt. Ltd. Patalganga plant 2020 2025 1992 2004 Deleveraged through strategic • Modernised the facilities with Established 1st plant for Wander Limited merged with Pearl sale of brands to Cipla worth an investment of ₹48 crore manufacturing APIs Organics Limited → Renamed ₹87 crore Wanbury Limited • 6th successful USFDA inspection 1995 2021 for Patalganga plant (zero 483 Acquired Brij Chemicals’ plant 2006 Capital infusion observations) at Patalganga (Maharashtra) Acquired Doctor's Organic and of ₹50 crore through Chemicals Limited (DOCL) with a Preferential Issue • Successful ANVISA audit 1995 multi-purpose USFDA-approved clearance for Tanuku plant Acquired Wander Limited → facility in Tanuku 2023 • Refinanced Neo AIF Debt at a subsidiary of Sandoz (Brand • Raised ₹95 crore via NCD lower interest rate Formulation Business) 2007 from Neo AIF • DOCL merged with Wanbury 2026 1996 Limited • Settlement with all the • Achieved highest-ever lenders Formed a strategic alliance • Listing on NSE & BSE Operational EBITDA of ₹108 with Wyckoff Chemicals (US) crore • Acquired Cantabria Pharma to market APIs in US S.L. (Spain) - Present in ethical branded formulations in European market Investor Presentation | Wanbury Limited 01/ COMPANY PROFILE Successful Business Turnaround Financial Turnaround Operational Turnaround Debt reduction: ~75% reduction from peak- Capacity ramp-up in key existing API debt obligation of ~700 Crores, including products through de-bottlenecking: corporate guarantee from Wanbury Limited Metformin (25% increase in last 3 years) to Wanbury Holding B.V. (Netherland) for & Sertraline (20% increase in last 3 years) foreign debt held by Netherlands subsidiary Debt refinancing: Reduction in borrowing Operational profitability: ~4X EBITDA cost from 22.5% to 12.5% with effected from scale-up between FY23-FY26, through 1st March 2025, with scope for further de-bottlenecking projects & production scale- reduction in coming years up, efficient procurement practises, technical savings, among others Exited all high cost private financial Envisaged break-even profitability in agreements Formulations business, delivered financial break-even in FY26 Investor Presentation | Wanbury Limited 01/ COMPANY PROFILE Wanbury at a Glance 6 products, 10+ brands, 2 USFDA acute & approved API 100% chronic semi-chronic facilities portfolio Formulations Portfolio with 386 KL cumulative API Portfolio reactor capacity 80%+ 1,200+ 37+ years Export top line, with Employee strength Operating history emphasis on developed markets Regulatory Dual revenue-stream Approvals API Formulation Investor Presentation | Wanbury Limited 01/ COMPANY PROFILE Business Streams API Formulations API manufacturer building a niche, Rebuilding legacy brand formulations profitable & sustainable business business in India (50%+ Gross contribution margins) 10+ active brands + additional Diversified business stream across launches in pipeline 6 products + additional launches ₹650 Crore in pipeline FY26 Revenue Key therapeutic categories such as Anti cold & cough, Anti-infective, Anti- Regulatory markets focused (EU, inflammatory, Supplements, Brazil, US) mature & sustainable API Orthopaedic, among others business 88% ₹574 Crore ₹76 Crore FY26 Revenue FY26 Revenue Formulations Investor Presentation | Wanbury Limited 01/ COMPANY PROFILE Board of Directors Mr. Mohan Kumar Mr. K. Dr. Anupama Mr. Mridul Mr. Manoj Mr. Pallavur Rayana Chandran Vaidya Mehta Gursahani Sankar Das Promoter & Whole Time Whole Time Director Non Executive Non Executive Non Executive Non Executive Director Independent Woman Independent Director Independent Director Independent Director Director 25+ years of experience 30+ years of experience 30+ years of experience 30+ years of experience 35+ years of experience 35+ years of experience He holds a Bachelor of He graduated with a She holds a Bachelor’s He holds a BE in Computer He serves as the Executive He is an accomplished Pharmacy from the Bachelor of Science from degree in Computer Science from Maharaja Director of the Mumbai– leader with more than 35 University of Mumbai and t [Showing first 8,000 characters — download PDF for full document]